EA201100427A1 - Гетероциклические ингибиторы киназы - Google Patents

Гетероциклические ингибиторы киназы

Info

Publication number
EA201100427A1
EA201100427A1 EA201100427A EA201100427A EA201100427A1 EA 201100427 A1 EA201100427 A1 EA 201100427A1 EA 201100427 A EA201100427 A EA 201100427A EA 201100427 A EA201100427 A EA 201100427A EA 201100427 A1 EA201100427 A1 EA 201100427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
compositions
kinase inhibitors
inhibiting
activity
Prior art date
Application number
EA201100427A
Other languages
English (en)
Inventor
Маттью Бергер
Цзион Лань
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201100427A1 publication Critical patent/EA201100427A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Описаны новые соединения, композиции и способы ингибирования активности провирусной интеграции киназы Maloney (киназы PIM), связанной с опухолегенезом у человека или животного. В некоторых вариантах осуществления соединения и композиции эффективны для ингибирования активности по крайней мере одной киназы PIM. Новые соединения и композиции могут использоваться отдельно или в комбинации по крайней мере с одним дополнительным агентом для лечения нарушений, опосредованных серин/треонинкиназой или рецепторной тирозинкиназой, таких как рак.
EA201100427A 2008-09-02 2009-08-31 Гетероциклические ингибиторы киназы EA201100427A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9366408P 2008-09-02 2008-09-02
PCT/EP2009/061188 WO2010026122A1 (en) 2008-09-02 2009-08-31 Heterocyclic pim-kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201100427A1 true EA201100427A1 (ru) 2011-10-31

Family

ID=41170173

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100427A EA201100427A1 (ru) 2008-09-02 2009-08-31 Гетероциклические ингибиторы киназы

Country Status (11)

Country Link
US (1) US8759338B2 (ru)
EP (1) EP2344473B1 (ru)
JP (1) JP5584215B2 (ru)
KR (1) KR20110056399A (ru)
CN (1) CN102197032B (ru)
AU (1) AU2009289317A1 (ru)
BR (1) BRPI0918846A2 (ru)
CA (1) CA2735782A1 (ru)
EA (1) EA201100427A1 (ru)
MX (1) MX2011002362A (ru)
WO (1) WO2010026122A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2455382T3 (da) 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
PT3070090T (pt) 2007-06-13 2019-03-20 Incyte Holdings Corp Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SG183551A1 (en) 2010-03-10 2012-10-30 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG185567A1 (en) 2010-05-21 2012-12-28 Incyte Corp Topical formulation for a jak inhibitor
UA113156C2 (xx) 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5876146B2 (ja) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
JP6105578B2 (ja) 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2919766B1 (en) 2012-11-15 2021-05-26 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
BR122019024759B1 (pt) 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108373476B (zh) * 2017-01-13 2021-06-01 成都地奥制药集团有限公司 一种激酶抑制剂及其制备和应用
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CR20200379A (es) 2018-01-30 2021-03-05 Incyte Corp Procesos e intermedio para elaborar un inhibidor de jak campo técnico
IL302865A (en) 2018-03-30 2023-07-01 Incyte Corp Use of JAK inhibitors to treat hidradenitis suppurativa
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
CN111362922A (zh) * 2018-12-26 2020-07-03 上海喆邺生物科技有限公司 2,4-二氨基嘧啶衍生物及其用途
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2004081000A1 (en) 2003-03-10 2004-09-23 Astrazeneca Ab Quinazoline derivatives
WO2004108707A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
US7390907B2 (en) * 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
EP1781293A1 (en) * 2004-06-04 2007-05-09 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
AU2006284900A1 (en) * 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
BRPI0712737A2 (pt) 2006-06-13 2012-05-08 Wyeth Corp composto; composição farmacêutica; método e tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteìna quinase em um mamìfero; e uso do composto
WO2008028168A2 (en) * 2006-09-01 2008-03-06 Cylene Pharmaceuticals, Inc. Serine-threonine protein kinase and parp modulators
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use

Also Published As

Publication number Publication date
JP2012501313A (ja) 2012-01-19
JP5584215B2 (ja) 2014-09-03
CA2735782A1 (en) 2010-03-11
AU2009289317A1 (en) 2010-03-11
WO2010026122A1 (en) 2010-03-11
BRPI0918846A2 (pt) 2019-09-24
MX2011002362A (es) 2011-04-04
CN102197032B (zh) 2014-07-23
US8759338B2 (en) 2014-06-24
EP2344473A1 (en) 2011-07-20
US20110195956A1 (en) 2011-08-11
KR20110056399A (ko) 2011-05-27
CN102197032A (zh) 2011-09-21
EP2344473B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
CY1113680T1 (el) Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10
EA201690033A2 (ru) Морфинановые соединения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201000428A1 (ru) Оксадиазол- и оксазолзамещенные производные бензимидазола и индола как ингибиторы dgat1
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
UA94055C2 (en) Substituted benzimidazoles and methods of preparation
JO3055B1 (ar) مشتقات بيكوليناميد كمثبطلت كيناز
TN2011000070A1 (en) Picolinamide derivatives as kinase inhibitors